[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"macular-edema-secondary-to-inflammation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:macular-edema-secondary-to-inflammation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100592642","phase-3-a-phase-3-study-to-evaluate-the-efficacy-and-safety-of-intravitreal-ksi-101-in-participants-with-macular-edema-secondary-to-inflammation-mesi---pinnacle-100592642",false,"NCT06996080","A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE","A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE","PINNACLE","Inclusion Criteria:\n\n* Macular Edema Secondary to Inflammation (MESI) with a central subfield thickness (CST) of ≥320 and \\\u003C400 microns on SD-OCT and a BCVA score of ≥25 and ≤78 ETDRS letters (between \\~20\u002F25 and 20\u002F320 Snellen equivalent) in the Study Eye.\n* Definitive presence of Intraretinal Fluid and\u002For Subretinal Fluid on SD-OCT in the Study Eye.\n* Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic in the Study Eye.\n\nExclusion Criteria:\n\n* ME in the Study Eye secondary to diabetes, RVO, or wAMD.\n* Active or suspected ocular or periocular infection in either eye.\n* Any history of or active occlusive retinal vasculitis in either eye.","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)",[27],"Macular Edema Secondary to Inflammation",[29,30,31,32],"MESI","macular edema","inflammatory macular edema","macular edema associated with inflammation","RECRUITING","2026-05-14",{"date":36,"type":37},"2026-05-18","ACTUAL",{"date":39,"type":37},"2025-07-16",{"date":41,"type":21},"2027-08",{"name":43,"class":44},"Kodiak Sciences Inc","INDUSTRY",56,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":25,"conditions":57,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":45},"100592205","phase-3-a-phase-3-study-to-evaluate-the-efficacy-and-safety-of-intravitreal-ksi-101-in-participants-with-macular-edema-secondary-to-inflammation-mesi---peak-100592205","NCT06990399","A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK","A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK","PEAK","Inclusion Criteria:\n\n* Macular Edema Secondary to Inflammation (MESI) with a central subfield thickness (CST) of ≥400 microns on SD-OCT in Study Eye.\n* Definitive presence of Intraretinal Fluid and\u002For Subretinal Fluid on SD-OCT in the Study Eye.\n* BCVA ETDRS score of ≥25 and ≤70 letters (between 20\u002F40 and 20\u002F320 Snellen equivalent) in the Study Eye.\n* Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic in the Study Eye.\n\nExclusion Criteria:\n\n* Macular Edema in the Study Eye secondary to diabetic retinopathy, RVO, or wAMD.\n* Active or suspected ocular or periocular infection in either eye.\n* Any history of or active occlusive retinal vasculitis in either eye.",{"count":55,"type":21},600,[24],[27],[29,30,31,32],{"date":36,"type":37},{"date":61,"type":37},"2025-07-30",{"date":63,"type":21},"2027-11",{"name":43,"class":44}]